Anti-VEGF Shows Promise for Treating Radiation Retinopathy

Amy Schefler, MD

Show Description +

Amy Schefler, MD, FACS, FASRS, shares 1-year outcomes for patients with radiation retinopathy treated with intravitreal aflibercept (Eylea, Regeneron) on a treat-and-extend basis.

Posted: 7/26/2022

Keywords:

Ocular Oncology

•

Radiation

•

Intravitreal Injection

•

aflibercept

•

Treat and Extend

•

retina-meeting-recap

Up Next

Name: Anti-VEGF Shows Promise for Treating Radiation Retinopathy
Uploaded: 2022-07-26T18:55:57+00:00
Description: Amy Schefler, MD, FACS, FASRS, shares 1-year outcomes for patients with radiation retinopathy treated with intravitreal aflibercept (Eylea, Regeneron) on a treat-and-extend basis.

Faricimab in Wet AMD After 2 Years

Arshad M. Khanani, MD, MA

Retinal Fluid Data Revealed for the PDS

Aleksandra V. Rachitskaya, MD, FASRS

High-Dose Aflibercept: Promising Results

Lloyd Clark, MD, FASRS

Dual Blockade Improves Durability for DME Treatment

David Eichenbaum, MD

Home Monitoring for AMD: 10 Years of Data

Michael J. Elman, MD

A Call for Inclusion Efforts in Retina Clinical Trials

Vivienne S. Hau, MD, PhD

Back to All Videos

Anti-VEGF Shows Promise for Treating Radiation Retinopathy

Amy Schefler, MD

Amy Schefler, MD, FACS, FASRS, shares 1-year outcomes for patients with radiation retinopathy treated with intravitreal aflibercept (Eylea, Regeneron) on a treat-and-extend basis.

Posted: 7/26/2022

Keywords:

Ocular Oncology

•

Radiation

•

Intravitreal Injection

•

aflibercept

•

Treat and Extend

•

retina-meeting-recap

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Anti-VEGF Shows Promise for Treating Radiation Retinopathy

Up Next

Anti-VEGF Shows Promise for Treating Radiation Retinopathy

More From ASRS: 2022 Coverage